BR0108107A - Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação - Google Patents
Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinaçãoInfo
- Publication number
- BR0108107A BR0108107A BR0108107-1A BR0108107A BR0108107A BR 0108107 A BR0108107 A BR 0108107A BR 0108107 A BR0108107 A BR 0108107A BR 0108107 A BR0108107 A BR 0108107A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- estrogen
- compositions
- estrogens
- practicing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MODULADORES SELETIVOS DOS RECEPTORES DE ESTROGêNIO EM COMBINAçãO COM ESTROGêNIOS; KITS E COMPOSIçõES FARMACêUTICAS PARA PRATICAR TAL COMBINAçãO; BEM COMO A ADMINISTRAçãO DA REFERIDA COMBINAçãO". São revelados métodos inovadores para redução ou eliminação da incidência de fogachos e sintomas menopáusicos, os quais ao mesmo tempo diminuem o risco de se adquirir câncer de mama ou endometrial e, além disso, tratam e/ou inibem o desenvolvimento de osteoporose, hipercolesterolemia, hiperlipidemia, aterosclerose, hipertensão, resistência a insulina, diabete, perda de massa muscular, obesidade, menstruação irregular, mal de Alzheimer ou Secura vaginal em animais de sangue quente (homeotérmicos) suscetíveis, incluindo seres humanos, envolvendo a administração de modulador seletivo de receptor de estrogênio, particularmente compostos que possuem a estrutura geral (I) e uma quantidade de estrogênio ou composto estrogênico/androgênico misturado. Ainda, administração de bisfosfonatos ou precursor de esteróide sexual é especificamente revelada para o tratamento médico e/ou inibição de desenvolvimento de algumas das doenças mencionadas acima. São também reveladas composições para dístribuição de ingrediente(s) ativo(s) e kit(s) úteis para a invenção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17860100P | 2000-01-28 | 2000-01-28 | |
PCT/CA2001/000086 WO2001054699A1 (en) | 2000-01-28 | 2001-01-26 | Selective estrogen receptor modulators in combination with estrogens |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0108107A true BR0108107A (pt) | 2003-03-11 |
Family
ID=22653187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0108107-1A BR0108107A (pt) | 2000-01-28 | 2001-01-26 | Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação |
Country Status (21)
Country | Link |
---|---|
US (3) | US20020198179A1 (pt) |
EP (1) | EP1251855A1 (pt) |
JP (1) | JP2003520817A (pt) |
KR (1) | KR20020073566A (pt) |
CN (1) | CN1400904A (pt) |
AR (1) | AR035564A1 (pt) |
AU (1) | AU2991301A (pt) |
BR (1) | BR0108107A (pt) |
CA (1) | CA2395730A1 (pt) |
CZ (1) | CZ20022401A3 (pt) |
HK (1) | HK1048761A1 (pt) |
HU (1) | HUP0204211A3 (pt) |
IL (1) | IL149990A0 (pt) |
MX (1) | MXPA02007165A (pt) |
NO (1) | NO20023484D0 (pt) |
NZ (1) | NZ534348A (pt) |
PL (1) | PL357163A1 (pt) |
RU (1) | RU2342145C2 (pt) |
SK (1) | SK9592002A3 (pt) |
WO (1) | WO2001054699A1 (pt) |
ZA (1) | ZA200205926B (pt) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2234060A1 (en) * | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
EP1296674A2 (en) * | 2000-07-06 | 2003-04-02 | Wyeth | Use of substituted indole compounds for increasing nitric oxide synthase activity |
AU2001273144A1 (en) * | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating neuropeptide y-related conditions |
US6245819B1 (en) | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
ES2292775T3 (es) * | 2001-07-06 | 2008-03-16 | Penwest Pharmaceuticals Co. | Formulaciones de liberacion prolongada de oximorfona. |
SK622004A3 (en) * | 2001-07-31 | 2004-08-03 | Pfizer Prod Inc | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
TW200307553A (en) * | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
CN100448437C (zh) * | 2002-06-06 | 2009-01-07 | 霍尔莫斯医疗有限公司 | 抑制女性萎缩或治疗或预防与女性萎缩相关的症状的方法 |
US20060134191A1 (en) * | 2003-05-23 | 2006-06-22 | Pieter De Haan | Immediate-release pharmaceutical dosage form comprising polymorphous tibolone |
US20080227814A1 (en) * | 2004-01-29 | 2008-09-18 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
EP2407462B1 (en) | 2004-09-21 | 2014-07-30 | Marshall Edwards, Inc. | Substituted chroman derivatives, medicaments and use in therapy |
ES2553101T3 (es) * | 2004-10-20 | 2015-12-04 | Endorecherche Inc. | Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas |
JP2008530210A (ja) * | 2005-02-16 | 2008-08-07 | ワイス | 放射線または化学療法誘発粘膜炎および放射線膀胱炎のためのエストロゲン受容体−β選択性アゴニストの使用 |
EP2034984A4 (en) | 2006-06-02 | 2013-03-06 | Pear Tree Women S Health Care | PROCESS FOR TREATING ATROPHIC VAGINITIS |
ES2436028T3 (es) * | 2006-06-23 | 2013-12-26 | Radius Health, Inc. | Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno |
WO2008101030A1 (en) * | 2007-02-13 | 2008-08-21 | The Regents Of The University Of California | Methods for amplifying steroid hormone effects |
ES2590262T3 (es) | 2007-02-14 | 2016-11-21 | Hormos Medical Ltd. | Método para la preparación de derivados de trifenilbuteno con valor terapéutico |
WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
US20140040862A1 (en) * | 2008-04-03 | 2014-02-06 | Adobe Systems Incorporated | Copying Reusable Components from a Remote Source |
AU2014201406B2 (en) * | 2009-06-16 | 2016-08-11 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
AU2016235019B2 (en) * | 2009-06-16 | 2018-06-28 | Endorecherche, Inc. | Treatment of alzheimer's disease, loss of cognition, memory loss, and dementia with sex steroid precursors in combination with selective estrogen receptor modulators |
US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
EP2568806B1 (en) | 2010-05-12 | 2016-05-11 | Radius Health, Inc. | Therapeutic regimens |
MX2012014431A (es) * | 2010-06-10 | 2013-02-26 | Aragon Pharmaceuticals Inc | Modulares del receptor de estrogenos y usos de los mismos. |
US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
US9708283B2 (en) | 2010-11-01 | 2017-07-18 | Mei Pharma, Inc. | Isoflavonoid compositions and methods for the treatment of cancer |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
MD20140054A2 (ro) | 2011-12-16 | 2014-10-31 | Olema Pharmaceuticals, Inc. | Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora |
CN102584687A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
AU2013221478B2 (en) * | 2012-02-14 | 2017-06-01 | Repros Therapeutics Inc. | Selective estrogen receptor modulators with short half-lives and uses thereof |
CN102631677A (zh) * | 2012-04-19 | 2012-08-15 | 中国农业大学 | 一种预防和/或治疗动脉粥样硬化的药物组合物 |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
CN104994877A (zh) | 2012-11-02 | 2015-10-21 | 利普生物药剂公司 | 用于癌症治疗的反式-克罗米芬 |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
US9744177B2 (en) * | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
PL3122426T3 (pl) | 2014-03-28 | 2023-05-15 | Duke University | Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP3174542A4 (en) | 2014-07-29 | 2018-01-03 | TherapeuticsMD, Inc. | Transdermal cream |
CA2974123C (en) | 2015-02-02 | 2023-08-01 | Mei Pharma, Inc. | Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
BR112018070199A2 (pt) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | composição farmacêutica de hormônio esteroide |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3525774B1 (en) | 2016-10-11 | 2021-12-29 | Duke University | Lasofoxifene treatment of er+ breast cancer |
CN117417263A (zh) | 2017-01-05 | 2024-01-19 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
US20180207177A1 (en) * | 2017-01-23 | 2018-07-26 | Government Of The United States As Represented By The Secretary Of The Air Force | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2) |
CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
US5446061A (en) * | 1993-11-05 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5446071A (en) * | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5897539A (en) * | 1995-09-28 | 1999-04-27 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
ATE206701T1 (de) * | 1996-04-19 | 2001-10-15 | American Home Prod | Östrogene verbindungen |
ZA987554B (en) * | 1997-08-21 | 2000-02-21 | American Home Prod | Methods for the solid phase synthesis of substituted indole compounds. |
US7005428B1 (en) * | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
DE19916419B4 (de) * | 1999-04-08 | 2005-06-16 | Schering Ag | Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose |
AU5957500A (en) * | 1999-07-06 | 2001-01-22 | Endorecherche Inc. | Methods of treating and/or suppressing weight gain |
-
2001
- 2001-01-26 MX MXPA02007165A patent/MXPA02007165A/es not_active Application Discontinuation
- 2001-01-26 BR BR0108107-1A patent/BR0108107A/pt not_active Application Discontinuation
- 2001-01-26 CZ CZ20022401A patent/CZ20022401A3/cs unknown
- 2001-01-26 KR KR1020027009728A patent/KR20020073566A/ko not_active Application Discontinuation
- 2001-01-26 AU AU29913/01A patent/AU2991301A/en not_active Abandoned
- 2001-01-26 IL IL14999001A patent/IL149990A0/xx unknown
- 2001-01-26 SK SK959-2002A patent/SK9592002A3/sk not_active Application Discontinuation
- 2001-01-26 HU HU0204211A patent/HUP0204211A3/hu unknown
- 2001-01-26 JP JP2001554683A patent/JP2003520817A/ja active Pending
- 2001-01-26 AR ARP010100372A patent/AR035564A1/es unknown
- 2001-01-26 NZ NZ534348A patent/NZ534348A/en active IP Right Revival
- 2001-01-26 EP EP01902194A patent/EP1251855A1/en not_active Withdrawn
- 2001-01-26 RU RU2002123047/14A patent/RU2342145C2/ru not_active IP Right Cessation
- 2001-01-26 CN CN01804028A patent/CN1400904A/zh active Pending
- 2001-01-26 WO PCT/CA2001/000086 patent/WO2001054699A1/en active Application Filing
- 2001-01-26 CA CA002395730A patent/CA2395730A1/en not_active Abandoned
- 2001-01-26 PL PL01357163A patent/PL357163A1/xx not_active Application Discontinuation
- 2001-11-07 US US10/052,803 patent/US20020198179A1/en not_active Abandoned
- 2001-11-07 US US10/052,824 patent/US20030040510A1/en not_active Abandoned
-
2002
- 2002-05-09 US US10/143,894 patent/US20030065008A1/en not_active Abandoned
- 2002-07-22 NO NO20023484A patent/NO20023484D0/no not_active Application Discontinuation
- 2002-07-24 ZA ZA200005926A patent/ZA200205926B/xx unknown
-
2003
- 2003-02-06 HK HK03100850.6A patent/HK1048761A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20022401A3 (cs) | 2003-10-15 |
RU2342145C2 (ru) | 2008-12-27 |
NO20023484L (no) | 2002-07-22 |
NZ534348A (en) | 2006-06-30 |
US20030065008A1 (en) | 2003-04-03 |
SK9592002A3 (en) | 2003-12-02 |
KR20020073566A (ko) | 2002-09-27 |
NO20023484D0 (no) | 2002-07-22 |
ZA200205926B (en) | 2003-07-24 |
MXPA02007165A (es) | 2003-09-22 |
CN1400904A (zh) | 2003-03-05 |
JP2003520817A (ja) | 2003-07-08 |
AR035564A1 (es) | 2004-06-16 |
WO2001054699A1 (en) | 2001-08-02 |
PL357163A1 (en) | 2004-07-26 |
CA2395730A1 (en) | 2001-08-02 |
AU2991301A (en) | 2001-08-07 |
HUP0204211A3 (en) | 2005-06-28 |
RU2002123047A (ru) | 2004-03-10 |
HUP0204211A2 (hu) | 2003-04-28 |
EP1251855A1 (en) | 2002-10-30 |
IL149990A0 (en) | 2002-12-01 |
US20020198179A1 (en) | 2002-12-26 |
US20030040510A1 (en) | 2003-02-27 |
HK1048761A1 (zh) | 2003-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0108107A (pt) | Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação | |
JP3441730B2 (ja) | デヒドロエピアンドロステロンの治療用途およびデリバリーシステム | |
CA2334702C (en) | Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol | |
AU643445B2 (en) | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia | |
BR9911116A (pt) | Processo para tratar ou reduzir o risco de adquirir uma condição selecionada dentre o grupo consistindo de aterosclerose, câncer endometrial, câncer uterino, câncer ovariano, falta de lubrificação vaginal, e perda de massa muscular, composição farmacêutica, e, kit. | |
NZ516502A (en) | Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG) | |
BRPI0516243C1 (pt) | uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit | |
UA73911C2 (en) | Method of treatment employing sex steroid precursors (variants), pharmaceutical composition and transdermal patches | |
NZ598270A (en) | Dhea compositions for treating menopause | |
JP7080117B2 (ja) | 性ステロイド前駆体とsermとの併用による男性アンドロゲン欠乏症状又は疾患の治療 | |
Nurrochmad et al. | Phytoestrogens of Pachyrhizus erosus prevent bone loss in an ovariectomized rat model of osteoporosis | |
López | New approaches to the treatment of osteoporosis | |
EP1526856A1 (en) | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy | |
Wuttke et al. | Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo-and conjugated estrogens-controlled study | |
Speroff et al. | Practical guidelines for postmenopausal hormone therapy | |
Wachtel | Plantar and palmar hyperkeratosis in young castrated women | |
BR0315374A (pt) | Compostos orgânicos | |
Pap et al. | Development of natural calcium-and phosphate-donating microparticles and a new iontophoretic apparatus for the topical treatment of local osteoporosis. Preliminary in vitro and in vivo studies | |
BR0314959A (pt) | Emplastro transdérmico de 17beta-estradiol/levonorgestrel para terapia de reposição hormonal | |
McCloskey | Aromatase inhibitors and bone health | |
AU2004200178A1 (en) | Pharmaceutical Compositions and Uses for Androst-5-ene-3B,17B-diol | |
Van Waart et al. | South African Menopause Society Council revised consensus position statement on menopausal hormone therapy: statement | |
CIG Media Group | Fulvestrant (Faslodex™, ICI 182,780) Is Active in Patients with Tamoxifen-Resistant Breast Cancer: Data from North American and European Randomized Trials | |
TH137260A (th) | การรักษาอาการร้อนวูบวาบ, กลุ่มอาการจากการปรับขนาดหลอดเลือด, และอาการเหงื่อท่วมตัวในตอนกลางคืนด้วยสารตั้งต้นของสเตอรอยด์ทางเพศในการรวมกันกับสารปรับคุมเอสโตเจน รีเซปเตอร์อย่างเลือกจำเพาะ | |
AU2006230652A1 (en) | Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10, 13, 24 E 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |